Compare Abbott Laboratories (ABT) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Abbott Laboratories trades at $95.62 (market cap $166.94B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $16.59. The key difference: Abbott Laboratories pays a 2.63% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | PDBC | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | — |
52-Week High | $136.62 | $18.91 |
52-Week Low | $82.57 | $12.90 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
PDBC trades at $16.32, up 2.84% today, with a bullish technical signal despite mixed moving averages and oscillators. The ETF has delivered strong returns, including 37% gains since March 2024, outperforming the S&P 500, though recent commodity momentum has softened. Its structure avoids K-1 tax forms, attracting $4.6 billion in assets as an inflation hedge.
Outlook remains cautiously optimistic given commodity price volatility and geopolitical risks. Opportunities include continued inflation hedging demand, but risks involve oil price declines and unpredictable annual distributions. Recent downgrade to hold reflects near-term caution amid supply disruptions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
